**Centers for Disease Control and Prevention** National Center for HIV, Viral Hepatitis, STD, and TB Prevention

### **NCHHSTP Update**

CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment

April 9, 2024

Jonathan Mermin, MD, MPH

Director, National Center for HIV, Viral Hepatitis, STD and TB Prevention



### **Quick Updates**

### **CDC Leadership Updates**

- Dr. Robyn Neblett Fanfair, Director of DHP
- Dr. Laura Hinkle Bachmann, Acting Director of DSTDP

### **Membership Updates**

- Welcome: Ms. Marguerite Beiser, Dr. Jorge Cestou, and Mr. Brigg Reilley
- Farewell to Dr. Jodie Dionne and Mr. Kali Lindsey

### Advancing Public Health through Policy and Partnerships

### Policy as a Public Health Intervention Cooperative Agreement (PS23-0009)

Multi-pronged and holistic approach to strengthen the ability of leaders who make decisions in public health to identify, assess, and implement evidence-based policy interventions.

<u>Component 1</u> Legal Epidemiology and Public Health Policy Research






#### Component 2

Development and Dissemination of Law and Policy Technical Assistance National Network of Public Health Institutes

### The NCHHSTP Office of Health Equity



- Celebrated a 20<sup>th</sup> Anniversary in 2023 with the release of an accomplishments video and internal CDC article
- Completed an extensive literature assessment to identify population-level, evidence-based interventions, policies, and best practices that can reduce disparities in HIV, viral hepatitis, STIs, TB and adolescent health
- Continued to lead the HHS CDC Equity Challenge Taskforce focused on inclusion of persons with lived experience of incarceration in the federal public health workforce
- Updated an Equity Dashboard with indicators and measures to monitor the Center's progress in reducing disparities

### **Cross-cutting project highlights**

#### **New NEEMA NOFO**

 On April 8, 2024 applications closed for the new 5 year cycle of the National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) Epidemiologic and Economic Modeling Agreement (NEEMA) CDC-RFA-PS-24-0028<sup>1</sup>, which is set to begin September 30, 2024.


#### **Routine Screening Toolkit**

- The Program and Performance Improvement Office, in collaboration with experts across NCHHSTP, has supported the American Medical Association (AMA) to develop release an online toolkit<sup>2</sup> to help physicians and other health care professionals increase routine screenings for HIV, STIs, viral hepatitis and latent tuberculosis (LTBI).
- The toolkit shares best practices and strategies for screening programs, specific to community health centers and emergency departments.

<sup>1.</sup> https://www.cdc.gov/nchhstp/neema/funding-opp-announcement.html

<sup>2.</sup> https://www.ama-assn.org/delivering-care/public-health/routinely-screen-hiv-stis-viral-hepatitis-and-latent-tb-infection

### Provisional 2023 TB surveillance data show rebound in TB cases following COVID-19 pandemic



### Tuberculosis Trials Consortium

**Tuberculosis Trials Consortium (TBTC)** for the 2021-2030 cycle • ..... Tuberculosis Trials ..... Consortium AFRICA CANADA UNITED STATES BENIN nton TB Clinic (#99) 1 wer Metro Tuberculosis Clinic (#2 SOUTH AFRICA itellenbosch University Partnership with DC VAMC. De choro Mosoltal (#333 UGAND HAIT on DC VA Medical Center, DC Health and WESTERN PACIFIC **O** VENDOR SITES AUSTRALIA VIET NAM VA MEDICAL CENTER SITES no Not District TB Unit (#76) 🛨 McGILL/CAB-V NETWORK est Clinic (#72) trict 6 TB Unit (#74) hol Viet Respiratory Centre (#75) 🖈

**Purpose:** Compare the safety and effectiveness of:

– 4-month bedaquiline (B), moxifloxacin (M) and pyrazinamide (Z) based regimens to

6-month standard of care

Population: Adult and adolescent patients with drug-susceptible pulmonary TB

**Design:** Open label, multi-center, randomized, <u>></u>3-arm adaptive trial

Sample size: 288 participants (96/arm)

Adaptive design: New arms of novel regimens which show promise in pre-clinical and early phase clinical trials can be added with concurrent enrollment of an equal number of controls

https://www.cdc.gov/tb/topic/research/tbtc/default.htm

**Study 38:** 

Combination

**Regimens for** 

**Shortening TB** 

Treatment

(CRUSH-TB)



### **Division of STD Prevention**

Laura Hinkle Bachmann, MD, MPH, FIDSA, FACP Acting Director




Released Two New Reports on STI Surveillance

Sexually Transmitted Infections Surveillance

2022

## *Vit*ålsigns<sup>™</sup>

### **STIs Continued To Climb in 2022**





### Cases of Congenital Syphilis Might Have Been Prevented With <u>Timely Testing</u> or <u>Adequate</u> Treatment During Pregnancy in 2022

McDonald R, O'Callaghan K, Torrone E, et al. Vital Signs: Missed Opportunities for Preventing Congenital Syphilis — United States, 2022. MMWR Morb Mortal Wkly Rep. ePub: 7 November 2023.


HHS Established a Multi-agency National Syphilis and Congenital Syphilis Syndemic Task Force

#### Goals

Reduce rates of primary and secondary syphilis and congenital syphilis

Reduce syphilis health disparities

**Jurisdictions: 14** 



### National Syphilis and Congenital Syphilis Syndemic Task Force Actions to Date

Conduct briefings with external partners for collaboration opportunities



Support a temporary import of Extencilline to address Bicillin® L-A shortage

> EXTENCILLINE 2.4 MUU brachine benyberitik Itiranusci riješte stil

Convene workshops to address disparities and focus on research strategies



Work with agencies to issue funding flexibility letters to grantees for syphilis care



### Newly Released and Upcoming Guidelines on STI Testing and Treatment

### CDC Laboratory Recommendations for Syphilis Testing, United States, 2024

February 8, 2024

### Doxycycline Post-Exposure Prophylaxis Guidance

Expected 2024 Release



### **Continued Investments in STI Prevention and Control**

#### Combatting Antimicrobial Resistant (AR) Gonorrhea and Other STIs (CARGOS)

Formerly GISP/eGISP and SURRG



Laboratory testing



Preparedness and outbreak response activities



Monitoring, detection, and response to AR in STIs



Epi-lab-health information technology

#### Support and Scale-Up of HIV Prevention Services in Sexual Health Clinics (SHIPS)

Formerly Part C of the Ending the HIV Epidemic in the U.S. Initiative





Strengthening clinic infrastructure and improving service delivery

Fostering strategic partnerships in support of EHE



### **Division of HIV Prevention**



#### Robyn Neblett Fanfair, MD, MPH Director



### **New NOFO!** PS24-0020: Capacity Building Assistance (CBA) for HIV Prevention Programs to End the HIV Epidemic in the United States

Supports the network of funded providers under this NOFO, established and referenced as the CBA Provider Network (CPN), to implement the following six inter-related program components:

- Component A: Technical Assistance to Enhance Integrated HIV Activities for Health Department Jurisdiction
- Component B: Instructor-led Training for High-Impact HIV Prevention Programs
- Component C: eLearning Training for High-Impact HIV Prevention Programs
- Component D: Technical Assistance for High-Impact HIV Prevention Programs
- Component E: Organization/Workforce Development and Management for Community-Based Organizations
- Component F: CPN Resource and Coordination Center



### **New NOFO!**

PS24 0047: High-Impact HIV Prevention and Surveillance Programs for Health Departments

5-year NOFO covering FY24 – FY29
60 Health Departments eligible for funding

• At Level Funding:

• Approximate yearly investment: \$485M

• Total 5-year investment: \$2,425,036,270

### **Core Strategies**

#### Diagnose

Increase knowledge of status to 95% by ensuring all people with HIV receive a diagnosis as early as possible.

#### Treat

Implement a comprehensive approach to treat people with diagnosed HIV infection rapidly (increase linkage to care up to 95%) and effectively to achieve viral suppression up to 95%.

#### Prevent

Prevent new HIV transmission by increasing PrEP coverage to 50%, increasing PEP services and supporting HIV prevention, including prevention of perinatal transmission, harm reduction and syringe services program (SSP) efforts.

#### Respond

Respond quickly to HIV clusters and outbreaks to address gaps and inequities in services for communities who need them.

#### Surveillance

Conduct HIV surveillance activities as described in the Technical Guidance for HIV surveillance programs to ensure accurate, timely, complete, and actionable data.

#### **Community Engagement**

Support community engagement and HIV planning.

### **Changes for Improved Impact**

#### **Increase Flexibility**

Implementing lessons learned from EHE successes and increasing flexibility for HDs to address specific community needs and innovate.

#### **Continuity of Services**

Added ability for CDC to fund other organizations to ensure continuity of critical programs if HD is unable or unwilling to receive CDC funding.

#### **Reduce Burden**

Reduce grantee reporting burden, moving to later in fiscal year to allow fewer funding packages, etc.



#### **Increase Funding Floor**

Funding floor has been increased for all jurisdictions from \$1M to \$1.2M.

#### **Strategic Alignment**

Required activities reflect National, HHS, and CDC strategic priorities – including community engagement, health equity, syndemics, and whole person approaches to HIV prevention.

#### **Funding Syndemics**

Applicants can use to 10% of the requested total funding amount to enhance syndemic efforts

### EHE Results from CDC-funded Programs 2021 – 2023

### 518,000 free HIV self-test kits

831,000 HIV tests & 3,000 people newly diagnosed\*

More than 55,000 persons prescribed PrEP\*

261 SSPs, more than 60% are mobile<sup>^</sup>


### **Over 200 clusters detected**

Ending the HIV Epidemic

\*These data reflect efforts between Jan 2021 and June 2023 ^Information regarding SSPs is current as of 2022

### CDC EHE Results – Diagnose 2021 – 2023

CDC recipients used EHE funding to test over **831,000** persons for HIV infection, and 3,000 people were newly diagnosed



CDC is distributing free HIV self-test kits to populations disproportionately affected by HIV. After delivering **100,000** self-tests in the pilot, over **367,000** tests were delivered in 2023. **CDC EHE Results – Prevent** 2021 - 2023

Between Jan 2021 and June 2023, **CDC EHE-funded** programs prescribed PrEP for more than **55,000** persons

CDC EHE funded programs have connected with over 260 SSPs **168** mobile or - 60% of which provide mobile services

93 fixed

locations

outreach

locations

### **CDC Community Engagement Sessions**

Engaged 1,684 people through 16 in-person meetings, including an in-person Spanish language session, across 10 regions

#### WE'RE HERE TO .... **ENCOURAGE EMPOWER** ENGAGE **HIV PREVENTION AND CARE PRIORITIES** HHS REGION 6 VIRTUAL COMMUNITY TOWN HALL MEETING: **TUESDAY OCTOBER 25TH 2022** 12:30 - 2PM EST/ 11:30 - 1PM CST COURAGE • EMPOWER • ENGAGE **CDC AND HRSA JOINT VIRTUAL COMMUNITY LISTENING SESSION**

IPN

THURSDAY, NOVEMBER 2, 2023 • 10:30AM-12PM ET

**HHS REGIONS 1&2** 

### **Ongoing Community Engagement**



JAN. 31 CDC Conversations with Community: Houston, Texas FEB. 21 CDC Conversations with Community: Baton Rouge, LA

MARCH. 27 CDC Conversations with Community: Memphis, Tennessee MAY. 22 CDC Conversations with Community: Miami, Florida







### **Division of Viral Hepatitis**

Neil Gupta, MD, MPH Captain, US Public Health Service Chief, Epidemiology and Surveillance Branch



### Viral hepatitis surveillance & progress reports released in April 2024



VIRAL HEPATITIS SURVEILLANCE AND CASE MANAGEMENT

GUIDANCE FOR STATE, TERRITORIAL, AND LOCAL HEALTH DEPARTMENTS

### Viral Hepatitis Surveillance Report

United States, 2022




2024 NATIONAL PROGRESS BEDORT Viral Hepatitis



Department of Ith and Human Services ters for Disease trol and Prevention

### New data signal progress in reducing acute viral hepatitis



Reported acute cases


**Source:** CDC, National Notifiable Diseases Surveillance System. The number of estimated viral hepatitis cases was determined by multiplying the number of reported cases by a factor that adjusted for under-ascertainment and under-reporting (Klevens, et al).

### Hepatitis C virus infections and related deaths decline; accelerated progress required to meet 2030 goals


National Progress Report 2030 Goal Reduce estimated\* new hepatitis C virus infections by  $\geq$  90% (incremental 2025 goal of ≥20% reduction)

Estimated\* new hepatitis C virus infections and annual targets for the United States by year

80,000



Status: Moving toward annual target, but annual target was not fully met






### Jurisdictional support for viral hepatitis improving; great needs remain

#### **Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments**

- Completing 3<sup>rd</sup> year of 5-year funding cycle
- Hosting national meeting with jurisdictional partners April 16-17, 2024
- Sharing successes through rapid feedback reports and jurisdictional profiles




| laboratory tes  | nd Prevention (<br>health departm<br>ting, and public        | WHSP) proj<br>ents to eni<br>health rep | ect (2021-20<br>hance their v | funded recipient of CDC's<br>26). This investment suppo<br>iral hepatitis surveillance ar<br>M total annual funding). | rts 59 state, city | , county,                      |
|---|--|---|-------------------------------|---|--------------------|--------------------------------|
| JURISDICTION BACKGROUND<br>2022 NEW YORK CITY POPULATION <sup>1</sup><br>8.335,897 (2.5% of U.S. population)<br>2021 VIRAL HEPATITIS INCIDENCE <sup>2</sup> |  |   |                               | YEAR 3 PROJECT PERIOD<br>10/1/22-9/30/23<br>YEAR 3 NEW YORK CITY IVHSP AWARD?   |                    |                                |
|   |  |   |                               |   |                    |                                |
|   | NYC U.S.   | NYC                                     | <u>U.S.</u>                   | Viral hepatitis surveillance  | \$200,000          | 1.13                           |
| Hep A   | 1.1 1.7  | 90                                      | 5,728                         | Viral hepatitis prevention  | \$115,000          | 0.92                           |
| Acute hep 8   | 0.5 0.6  | 43                                      | 2,045                         | Special projects  | \$286,228          | 1.00                           |
| Acute hep C   | 1.5 1.6  | 130                                     | 5,023                         | Total   | \$601,228          |                                |
| SSPs<br>PERINATAL   | SSPs in ope<br>required; lo<br>not require                   |   | tration                       | Charles B Wang<br>Community<br>Health Center  | O Deper            | hemical<br>ndency<br>ment Cent |
|   |  | detection, c<br>from all he             | ase dispositio                | n, and assisted other jurisdicti<br>s to New York State Wadswor   |                    |                                |
| Year 3  | by sending serum<br>molecular testing                        |   |                               |   |                    |                                |
| Year 3<br>Highlights  | molecular testing<br>Published <u>Hepati</u>                 | tis A, B, and                           |                               | City: 2022 Annual Report  |                    |                                |
| Year 3<br>Highlights  | molecular testing  | is A. B. and<br>AK DETEC                | TION                          | City: 2022 Annual Report<br>IMPROVE MON<br>BURDEN, TREN   |                    |                                |
| Year 3<br>Highlights<br>Q ESTAI<br>AND<br>Status of hepa  | molecular testing<br>Published <u>Hepati</u><br>BLISH OUTBRE | ISA B, and<br>AK DETEC<br>AMEWOR        | TION                          | INPROVE MON   | DS, AND OUT        |                                |

#### 2022 Viral Hepatitis Surveillance Status Report

An assessment of the status of viral hepatitis surveillance practices across U.S. jurisdictions in 2022.

Jurisdictions with full-time employee dedicated to viral hepatitis surveillance

Though the number of jurisdictions with a full-time employee (FTE) dedicated to viral hepatitis surveillance increased from 68% in 2021 to 80% in 2022, 1/5 (20%) still did not have dedicated staffing in 2022.



HepVu 🔜

ANASTAD

Jurisdictions believe they need 3-5 FTEs to conduct viral hepatitis surveillance

To conduct viral hepatitis surveillance activities specified under CDC IVHSP, jurisdictions report that on average, they believe 3-5 full-time employees (FTE) are necessary.



Jurisdictions reported major challenges with hiring and retaining surveillance staff. Staff turnover was a significant impediment to conducting basic viral hepatitis surveillance activities in 2022.

### Ongoing efforts to establish national hepatitis C elimination initiative

VIEWPOINT

A National Hepatitis C Elimination Program in the United States A Historic Opportunity (Fleurence, RL, Collins FS, JAMA, 2023)

It is rare to have the opportunity, using a simple and safe oral medication, to eliminate a lethal disease. But that is the situation facing the United States with hepatitis C.

#### • Diagnosis

Implementation of universal screening recommendations

Accelerate availability of viral point-of-care testing (supporting test-and-treat)

#### Treatment

- Federal drug procurement (under- / un-insured)
- Integrate testing and treatment in primary care and other settings where people with hepatitis C receive care

#### • Comprehensive public health implementation

- Awareness campaigns, healthcare provider trainings
- Service integration (universal screening and treatment using innovative delivery systems tailored to settings where people with hepatitis C receive prevention and treatment services)
- Prevention activities (discovery, implementation)

### DASH Update for CHAC

Dr. Kathleen Ethier, Director

Centers for Disease Control and Prevention

National Center for Chronic Disease Prevention and Health Promotion

Division of Adolescent and School Health



### **Updated Mission and Vision for DASH 2.0**

Vision: We envision a future where young people are empowered with the knowledge, skills, and resources to support health and well-being.

Mission: To work with and through schools to understand and improve the health and well-being of all students. We do this by strengthening school-based education, health services, healthy school environments, and community connections.

### **Key Program Activities for 2024**

- Full stand-up of Health Schools Program (DP23-0002) to improve physical activity, nutrition, and management of chronic conditions
- Fund next NOFO to implement the What Works in Schools program
- Continue creating a more cohesive approach to school health

### **Key Surveillance and Research Activities for 2024**

- Release 2023 Youth Risk Behavior Survey (YRBS) Data Summary & Trends Report and YRBS data
- Improve interoperability of YRBS, Profiles and other datasets
- Launch research NOFO to examine What Works in Schools program expansion for schools serving rural and American Indian or Alaska Native youth
- Translate recent research findings to inform implementation of innovative school-based strategies

# New Resource: Mental Health Action Guide for School and District Leaders



Promoting Mental Health and Well-Being in Schools: An Action Guide for School and District Leaders

December 2023

Division of Adolescent and School Health (DASH) National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) Centers for Disease Control and Prevention (CDC)



In the **first two mon**ths after the release:



Received nearly 50,000 cumulative page views on action guide webpages.



Gave nearly 20 presentations to partners on action guide.




Detailed PDF downloaded more than 3,000 times.



27 federal and 5 partner accounts posted social media content on action guide, generating over 17.4 million impressions.

### New Data Release: 2022 Profiles and Profiles Explorer



- 2022 Profiles data highlights policies and practices schools are implementing to support adolescent health, including mental health
- Profiles Explorer allows users to explore nationwide, state, and district data in pre-created tables and maps.

## Thank you!

### For more information, contact: Advisory Committee Management Team nchhstppolicy@cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

